Obermatt
See Similar Stocks →

CytomX Therapeutics

NSQ:CTMX · US23284F1057
BiotechnologySmall

360

8
Profit price87
Cash yield1
Price/Sales39
EV / Gross Profit38
Price/Book53
Return on Capital51
Cash Return on Capital74
Return on Equity56
EBIT Margin14
Gross Profitability42
Accruals1
Owner Earnings Margin33
Sales growth23
Profit Growth60
Long-Term EPS Growth23
Reinvestment1
Price momentum32
Debt load78
Refinancing41
Debt Payback1
Liquidity1
Analyst ratings49
Expectations trend50
Market mood37
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

CytomX Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2010
Employees102
Websitecytomx.com
ISINUS23284F1057
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOncologyBiotechnologyHealth CareTherapeutics

Description

CytomX Therapeutics, Inc. (CytomX) operates as a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX leads the field of conditionally activated, mask…

Analysis

Middle-of-the-road

CytomX Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
37
2026

All-time high

44

Mar 2026

All-time low

37

Jun 2026

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
39
—
—
—
Price/Earnings
68
—
—
—
Price/Book
53
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
69
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare CytomX Therapeutics with its peers
Cullinan Therapeutics
NSQ:CGEM
61
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Black Diamond Therapeutics
NSQ:BDTX
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ALX Oncology Holdings
NSQ:ALXO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Janux Therapeutics
NMQ:JANX
41
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →